Singapore, Jul 2, 2009: Australian pharmaceutical company, Avexa has appointed Mr Lawrence Gozlan to its Board of Directors, replacing Dr John Sime who is retiring from the board. Dr Sime was appointed to the board as a non-executive director in June 2007, and Mr Gozlan will replace him in this capacity effective immediately.

“We are thrilled to welcome Mr Lawrence to our Board of Directors. His background in the life science industry as both a leading analyst and investor brings a unique and important perspective to our organization, and we look forward to his guidance and leadership as we continue to grow,” said Mr Nathan Drona, Chairman, Avexa. “I would also like to acknowledge Mr John’s significant contribution to the Avexa board over the last two years and wish him well for his future.”

Mr Lawrence Gozlan is the CEO and founder of Scientia Capital, a specialized global investment fund focused exclusively on life science. Prior to Scientia, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at Queensland Investment Corporation (QIC). He was also the senior biotechnology sell-side analyst on the equities team at Foster Stockbroking, and had corporate finance experience advising life science companies at Deloitte

“Avexa is at a critical juncture with apricitabine currently in phase III trials and the remainder of the pipeline progressing on track. I am excited to work with the company’s management and board of directors as we look to move the products forward through development,” stated Mr Lawrence Gozlan.